KRAS and non-small cell lung carcinoma: There is no directed treatment targeting KRAS, but the subsequent effector route, RAS/ RAF/MEK, possesses inhibitors which may be effective in patients with diagnosed NSCLC and mutant KRAS (Shames and Wistuba, 2014).